FRE Stock Overview
Engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Firebrick Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.052 |
| 52 Week High | AU$0.11 |
| 52 Week Low | AU$0.045 |
| Beta | 1.61 |
| 11 Month Change | -13.33% |
| 3 Month Change | -20.00% |
| 1 Year Change | -8.77% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.19% |
Recent News & Updates
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Shareholder Returns
| FRE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -11.8% | 1.5% |
| 1Y | -8.8% | 39.8% | 17.2% |
Return vs Industry: FRE underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: FRE underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: FRE's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Peter Molloy | www.firebrickpharma.com |
Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore.
Firebrick Pharma Limited Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | AU$11.35m |
| Earnings (TTM) | -AU$1.18m |
| Revenue (TTM) | AU$2.75m |
4.0x
P/S Ratio-9.3x
P/E RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | AU$2.75m |
| Cost of Revenue | AU$37.30k |
| Gross Profit | AU$2.71m |
| Other Expenses | AU$3.89m |
| Earnings | -AU$1.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0056 |
| Gross Margin | 98.64% |
| Net Profit Margin | -42.75% |
| Debt/Equity Ratio | 0% |
How did FRE perform over the long term?
See historical performance and comparison